News | November 02, 2006

Transplant Patients Offered Better Care with New Gene Test

A new alternative to invasive, painful biopsies for determining heart transplant rejection is both available and reimbursable. The molecular expression test molecular expression test is a non-invasive alternative to biopsy that is safe, effective, quantitative, and reproducible with predictive capabilities biopsy does not provide. The test provides physicians with a broader clinical picture, enabling them to identify patients at low risk for current and future rejection.

XDx, a molecular diagnostics company based in South San Francisco, CA, has announced expanded use and reimbursement for its first commercial offering, the AlloMap molecular expression test. Data from a recent study show that the testing method, which detects the absence of acute cellular rejection in heart transplant recipients, can now be used as early as two months post-transplant to rule out rejection.

The California Medicare contractor, National Heritage Insurance Company (NHIC) has recently made a decision to provide reimbursement coverage for the AlloMap test effective for claims submitted on or after Jan. 1, 2006. Medicare bills for AlloMap testing are currently billed through NHIC because the test is conducted by XDx in its South San Francisco, California clinical laboratory.

For more information visit

Related Content

Big Picture Genetic Scoring Approach Reliably Predicts Heart Disease
News | Genetic Testing | June 12, 2019
Specialized risk scores derived from testing that calculates the cumulative effect of an individual’s entire DNA...
The Corus CAD genetic test is a simple, noninvasive blood test that is clinically available for the assessment of obstructive coronary artery disease.

The Corus CAD gene expression test is a simple, noninvasive blood test that is available to assess a patient’s current likelihood of having obstructive coronary artery disease (CAD).


Feature | Genetic Testing | December 13, 2017 | Andrew Waxler, M.D., FACC
The diagnosis and management of cardiovascular disease has long followed a familiar approach.
genetic testing, sudden cardiac death of teen, Mayo Clinic Proceedings
News | Genetic Testing | November 09, 2016
The recent, sudden death of a 13-year-old boy resulted in more than 20 relatives being incorrectly diagnosed as having...
News | Genetic Testing | July 26, 2016
July 26, 2016 — A new study has identified a genetic error that weakens the aorta, placing patients with this and sim
Feature | Genetic Testing | December 22, 2015 | Kevin P. Greene, M.D.
Statins are lifesaving medications — they have been shown to greatly reduce heart attack and other related events by
Invitae Corp., cardiovascular test panels, genetic testing, expands offerings
Technology | Genetic Testing | October 08, 2015
Invitae Corp., a genetic information company, announced the expansion of its cardiology offering, including more than...
genomic testing, NGS, FDA, Precision Medicine Initiative, PMI, workshops
Feature | Genetic Testing | September 21, 2015
The U.S. Food and Drug Administration (FDA) will hold a pair of public workshops in November to explain ongoing efforts...
Overlay Init